
PUBLIC STS
WI13936
D8S1742
WI3831
D8S1413
WI8327
D8S277
WI14718
D8S561
WI3823
ND4
D8S1819
BAC
B0336E09
B0322E01
B0725B12
H28/B09
B0228F07
B0189E08
B0463F01
BIALLELIC MARKES
99-151
99-147
99-148
4-3
4-54
4-88
4-86
99-128
99-123
4-26
4-14
4-77
4-67
99-221
99-135
99-117

FIG. 1

ASSOCIATION STUDIES (FIRST SCREENING)

POPULATION SAMPLE SIZE	AFFECTED CASES= 112	NON AFFECTED CONTROLS=76
POPULATION CHARACTERISTICS	35 SPORADIC CASES +77 FAMILIAL CASES	>65 YEARS PSA<4



FIG.2

ASSOCIATION STUDIES (ZOOM)

	AFFECTED CASES (185)	UNAFFECTED CONTROLS (104)
CHARACTERISTICS OF POPULATIONS	47 SPORADIC CASES +138 FAMILIAL CASES	>65 YEARS PSA<4



FIG.3

HAPLOTYPE FREQUENCY ANALYSIS

POPULATIONS

	AFFECTED	UNAFFECTED
	CASES 2 (281)	CONTROLS 3 (130)
CHARACTERISTICS OF POPULATIONS	143 SPORADIC CASES +138 FAMILIAL CASES	>65 YEARS PSA<4

MARKERS	99-123	4-26	4-14	4-77	99-217	4-67	99-213	99-221	99-135	HAPLOTYPE FREQUENCIES		RELATIVE RISK	PVALUE
BACS	H0287B09	B0189E08		B0463F01					B0725B12				
CONTIGS	11453												
GENES	← PG1												
P VALUE	2,00E-01 *	1,00E-01 *	1,00E-01 *	2,00E-02 **	2,00E-02 **	6,00E-04 ***	9,00E-02 *	7,00E-01	2,00E-01 *	CASES .(2)	CONTROLS .(3)		
DISTANCE BETWEEN MARKERS(KB)		<18KB>	<15KB>	<88KB>	<22KB>	<17KB>	<15KB>	<29KB>	>100KB<				
HAPLOTYPE 8>304KB<	C	A	C	G	T	T	G	A	A	0,075	0,018	4,42	9,00E-04 ***
HAPLOTYPE 7>286KB<		A	C	G	T	T	G	A	A	0,095	0,016	6,46	6,00E-05 ****
HAPLOTYPE 6<186KB>		A	C	G	T	T	G	A		0,116	0,019	6,78	1,00E-05*****
HAPLOTYPE 5<171KB>			**C**	**G**	**T**	**T**	**G**	**A**		**0,117**	**0,013**	**10,06**	**9,00E-07********
HAPLOTYPE 4<83KB>				G	T	T	G	A		0,117	0,025	5,17	2,00E-05*****
HAPLOTYPE 3.1<54KB>					T	T	G	A		0,117	0,027	4,78	2,00E-05*****
HAPLOTYPE 3.2<54KB>				G	T	T	G			0,222	0,109	2,33	4,00E-05*****
HAPLOTYPE 2.2<39KB>				G	T	T				0,251	0,134	2,17	2,00E-04****
HAPLOTYPE 2<32KB>					T	T	G			0,226	0,112	2,32	1,00E-04***
HAPLOTYPE 1.1<17KB>					T	T				0,256	0,146	2,01	3,00E-04****
HAPLOTYPE 1.2<15KB>						T	G			0,233	0,129	2,05	6,00E-04***

FIG.4

HAPLOTYPE SIMULATIONS (100 ITERATIONS)

MARKERS	4-14	4-77	99-217	4-67	99-213	99-221	HAPLOTYPE FREQUENCIES CASES	CONTROLS	RELATIV RISK	PVALUE
HAPLOTYPE	C	G	T	T	G	A	0,117	0,013	10,06	9,00E-07



FIG.5A

HAPLOTYPE SIMULATIONS (100 ITERATIONS)

							HAPLOTYPE FREQUENCIES		RELATIV	PVALUE
MARKERS	4-144-77	99-217	4-67	99-213	99-221		CASES	CONTROLS	RISK	
HAPLOTYPE	C	G	T	T	G	A	0,117	0,013	10,06	9,00E-07



FIG.5B

BAC	MARKER	SEQ ID N°	SEQ ID N°(MUT)	PU SEQUENCE	SEQ ID N°	RP SEQUENCE	SEQ ID N°	POLYMORPHISM POSITION*	BASE	MICROSEQ. OLIGOS POSITIONS*	
228	99-123	21	30	AAAGCCAGGACTAGAAGG	39	TATTCAGAAAGGAGTGGG	48	24	C/T	1-23	25-47 (COMPLEMENTARY)
189	4-26	22	31	TACAGCCCTGTAAGACAC	40	TGAGGACTGCTAGGAAAG	49	24	A/G	1-23	25-47 (COMPLEMENTARY)
228/189	4-14	23	32	TCTAACCTCTCATCCAAC	41	GACTGTATCCTTTGATGCAC	50	24	C/T	1-23	25-47 (COMPLEMENTARY)
189/463	4-77	24	33	TGTTGATTTACAGGCGGC	42	GGAAAGGTACTCATTCATAG	51	24	G/C	1-23	25-47 (COMPLEMENTARY)
463	99-217	25	34	GGTGGGAATTTACTATATG	43	GTTTATTTTGTGTGAGCTTTG	52	24	C/T	1-23	25-47 (COMPLEMENTARY)
189/463	4-67	26	35	AAGTTCACCTTCTCAAGC	44	TGAAAGAGTTTATTCTCTGG	53	24	C/T	1-23	25-47 (COMPLEMENTARY)
463	99-213	27	36	ATACTGGCAGCGTGTGCTTC	45	TTATTGCCCCACATGCTTGAG	54	24	C/T	1-23	25-47 (COMPLEMENTARY)
463	99-221	28	37	CCCTTTTTCTTCACTGTTC	46	TCATTCGTCTGGCTAGGTC	55	24	A/C	1-23	25-47 (COMPLEMENTARY)
725	99-135	29	38	TGGAAGTTGTTATTGCCC	47	AAACACCTCCCATTGTGC	56	24	A/G	1-23	25-47 (COMPLEMENTARY)

FIG.6A

*: POSITIONS ARE GIVEN RELATIVE TO THE SEQUENCE OF THE CORRESPONDING MARKER (i.e. SEQ ID N°21-38 AND 57-62)

BAC	MARKER	SEQ ID N°	SEQ ID N°(MUT)	PU SEQUENCE	SEQ ID N°	RP SEQUENCE	SEQ ID N°	POLYMORPHISM POSITION*	BASE	MICROSEQ. OLIGOS POSITIONS*	
189/463	99-1482	57	60	ATCAAATCAGTGAAGTCTGAG	63	ACAAATCTATATAAGGCTGG	66	24	A/C	1-23	25-47 (COMPLEMENTARY)
463	4-73	58	61	ATCGCTGGAACATTCTGG	64	CTCTTGGTTAAACAGCAGTG	67	24	G/C	1-23	25-47 (COMPLEMENTARY)
463	4-65	59	62	GATTTAAGCTACGCTATTAG	65	TGGCTCTGCATTTCTTCC	68	24	C/T	1-23	25-47 (COMPLEMENTARY)

FIG.6B

*: POSITIONS ARE GIVEN RELATIVE TO THE SEQUENCE OF THE CORRESPONDING MARKER (i.e. SEQ ID N°21-38 AND 57-62)

EXON Phase	START	END	5' SPsite	PHASE	3' SPsite
Ex1 +0	2001	2216			GTGAGC
Ex2 +1	18196	18265	TAG	+0	GTTTGTA
Ex3 +0	23717	23832	CAG	+2	GTAACT
Ex4 +0	25571	25660	CAG	+0	GTAAGA
Ex5 +2	34669	34759	CAG	+0	GTAAGT
Ex6 +1	40688	40846	TAG	+1	GTAAGT
Ex7 +2	48070	48193	TAG	+2	GTGAGT
Ex8	50182	54523	TAG	+1	
ATG codon	2031	2033			
STOP codon	50405	50407			
POLY Ad site	54445	54450			

FIG. 7

PCT/US95/12860



FIG.8

FIG. 8B


Prostate Gene 1
Ex1
62aa
216bp
PseudoTyrPase
Ex2
23aa
Ex3
39aa
Ex4
30aa
Ex5
30aa
STOP
50
60
74
78
pA
Ex6
53aa
Ex7
41aa
Ex8
75aa-4.27kb

		box 1	box 2	box 3
PG1	Hs	NHQ *81-83*	FPEGTR *160-165*	LDAIYDVTV *211-219*
AF003136 (Genbank)	Ce	NHQ *630-632*	FPEGTR *712-717*	LDAIYDVTV *762-770*
Z72511 (Genbank)	Ce	48 NHR 50	FPEGTD *129-134*	VEYIYDITI *204-212*
P38226 (Swissport)	Sc	111 NHQ 113	FPEGTN *223-228*	IESLYDITI *271-279*
P33333 (Swissport)	Sc	81 NHQ 83	FPEGTR *154-159*	-
Z49770 (Genbank)	Sc	116 NHQ 118	FPEGTN *215-220*	LDAIYDVTI *265-273*
P26647 (Swissport)	Ec	72 NHQ 74	FPEGTR *145-150*	-
Z49860 (Genbank)	Bn	-	FVEGTR *90-95*	VPAIYDMTV *138-146*
U89336 (Genbank)	Hs	95 NHQ 97	FPEGTR *168-173*	-
U56417 (Genbank)	Hs	103 NHQ 105	FPEGTR *176-181*	-
AB005623 (Genbank)	Mm	100 NHQ 102	FPEGTR *173-178*	
Z29518 (Genbank)	Zm	91 NHR 93	FVEGTR *170-175*	VPAIYDTTV *218-226*

Hs = Homo sapiens, Ce = Caenorabibitis elegans, Ec = Escherichia coli;
Sc = Saccharomyces cerevisiae, Bn = Brassica napus, Zm = Zea maize,
Mm = Mus Musculus

- = pattern absent from protein sequence

Note: Funcitional acyl glycerol transferases all contain boxes 1 and 2 and not box 3. Proteins most related to PG1 contain the 3 boxes with a high degree of conservation.

FIG. 9



FIG. 10

Patent Application



FIG. 11



FIG. 12



PNT2 PG1 mut229

FIG. 13

FIG. 14A

FIG. 14

FIG. 14A
FIG. 14B




ID 121
ex1
ex2
ex3
ex4
ex7
ex8
ID 114
ex1
ex4
ex5
ex7
ex8
ID 122
ex1
ex2
ex3
ex4
ex5
ex6b (60bp)
ex7
ex8
ID 119
ex1
ex2
exon 1b (60bp)
ex3
ex4
ex5
ex6
ex7
ex8
ID 113
ex1
ex3
exon 3b (90bp)
ex4
ex5
ex6
ex7
ex8
ID 124
ex1
ex2
ex3
ex4
ex5
exon 5b (100bp)
ex6
ex7
ex8
ID 123
ex1
ex2
ex3
ex4
ex5
ex7
ex8

FIG. 14B

Combination of exons of PG1 gene discovered by PCR with primers specific for exon borders

Printer	Clones	prostate	PNT1A	PNT1B	PNT2	LnCaPFCG	LNCaPJMB	CoHPV	Du145	PC3	ECP5	ECP6	ECP7	ECP8	ECP9	ECP10	ECP11	ECP12	ECP13	ECP14	ECP15	ECP16	ECP17	ECP18	ECP19	ECP20	ECP21	ECP22	ECP23	ECP24
PG1exon13	+	+	+	+	+	[+]	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon14	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon15	+	−	−	−	−	−	−	NT	−	−	+	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon16	−	+	−	+	+	−	−	NT	−	−	−	−	+	−	−	−	−	−	−	−	−	−	−	−	−	−	+	−	−	−
PG1exon17	+	+	+	+	+	+	+	NT	+	+	−	−	+	−	−	−	+	+	+	+	+	+	+	−	−	+	+	−	+	+
PG1exon18	+	+	+	+	+	−	−	NT	+	+	−	−	−	−	−	−	−	−	−	−	+	−	−	−	−	−	−	−	−	−
PG1exon24	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon25	+	+	−	+	+	−	−	NT	+	−	−	−	−	−	−	+	−	−	−	+	−	−	−	−	−	−	−	−	+	+
PG1exon26	−	+	−	+	+	+	+	NT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon27	−	−	−	+	+	−	−	NT	+	−	−	−	−	−	−	−	+	−	−	+	−	−	−	−	−	−	−	−	+	+
PG1exon28	−	−	+	−	−	−	−	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon35	−	+	+	+	+	+	+	NT	+	+	−	−	−	−	−	−	+	+	−	+	+	+	−	−	+	+	+	+	−	−
PG1exon36	−	+	+	+	+	+	+	NT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon37	−	−	−	−	−	−	−	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon38	−	−	−	−	−	−	−	NT	−	+	−	−	−	−	−	−	−	−	−	−	+	−	−	−	−	−	+	−	−	−
PG1exon46	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon47	+	+	+	+	+	+	+	NT	+	+	+	−	+	+	−	+	+	−	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon48	−	−	−	−	+	−	−	NT	−	−	−	−	+	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon57	+	+	+	+	+	+	+	NT	+	+	+	+	+	−	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon58	−	−	−	−	−	+	+	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	+	−	−
PG1exon68	−	+	+	−	+	+	+	NT	+	+	−	−	−	−	+	+	−	−	+	+	−	−	+	−	−	−	+	−	+	+
PG1exon11b	+	+	+	+	+	+	+	NT	+	+	−	+	−	+	+	+	+	+	+	+	−	−	+	−	−	+	+	+	−	+
PG1exon1b2	+	+	+	+	+	+	+	NT	+	+	−	+	−	+	+	+	+	+	+	+	−	−	+	−	−	+	+	+	−	+
PG1exon1b3		+	−	+	+	+	+	NT	+	+	+	+	−	+	+	+	+	+	+	+	+	+	+	+	−	+	+	−	−	+	−
PG1exon1b4		+	−	+	+	+	+	+	+	+	−	−	+	−	+	+	−	−	−	+	+	+	+	−	+	+	−	−	+	−
PG1exon1b5		+	−	+	+	+	+	NT	+	+	−	−	+	−	−	−	+	+	−	−	+	−	+	−	−	+	+	+	+	−
PG1exon1b6		+	−	+	+	+	+	NT	+	+	+	+	+	−	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon1b7		+	−	+	+	+	+	NT	+	+	+	+	−	−	−	+	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon1b8		−	−	+	−	+	−	NT	−	−	−	+	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon3b4	+	+	+	−	+	+	+	NT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon3b5		−	−	+	+	−	−	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon3b6		+	+	+	+	+	+	NT	+	+	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon3b7		+	−	+	+	−	+	NT	−	+	−	+	−	−	−	−	−	−	−	−	+	+	−	−	+	−	−	−	−	−
PG1exon3b8		−	−	−	−	−	−	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon5b6	+	+	−	−	−	−	+	NT	−	+	−	+	−	−	−	−	+	+	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon5b7		+	−	+	+	+	+	NT	+	−	−	−	−	−	−	−	−	−	−	−	−	+	−	−	−	−	−	−	−	−
PG1exon5b8		−	−	−	+	−	−	NT	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−	−
PG1exon56b	+	+	−	+	+	+	+	NT	+	+	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon46b		+	−	+	+	+	+	NT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon36b		+	+	+	+	+	+	NT	+	+	+	+	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon26b		+	+	+	+	+	+	NT	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
PG1exon16b		+	+	+	+	+	+	NT	+	+	+	+	+	−	+	−	+	+	+	+	+	+	+	+	+	+	+	+	+	+

[+] alternative splicing form with combination of exons 13478 instead of 1345678

FIG. 15

FIG. 16


HAPLOTYPE ASSOCIATION STUDIES
FREQUENCY ANALYSIS (chrom 8p23)
POPULATIONS
characteristics of populations
AFFECTED N= [275;491]
ALL CASES
[275,491] all cases
UNAFFECTED N=[130;313]
CONTROLS
& <289 <28 unaffected (65 years or older) controls (65 years or older with PSA<4)
-Log dbs log or pvalue
markers of haplotype
B0322E01
H27B09
B0228F07
B0189E08
B0463F01
B075B12
pvalue HAPL. (Bac B0189E08 & B0463F01) = 3.4E-06
pvalue ASS. (99-576/421) = 3E-03
99-217/277
4-14/240
4-66/145
99-221/377
1,00E05
1,00E-03
1,00E-02
5,00E-02
ASSOCIATION (by marker)
HAPLOTYPE_max by Bac
Zoom
distance in kb
0
50
100
150
200
250
300
350
400
450
500
550
600
650
1
2
3
4
5

FIG. 17

ASSOCIATION STUDIES
PG1 (8p23)

POPULATIONS	AFFECTED N= [275;491]			UNAFFECTED N=[130;313]
	ALL CASES	SPORADIC CASES	FAMILIAL CASES	CONTROLS
characteristics of populations	<=491 all cases	<=294 sporadics cases	<=197 familial cases	<28 unaffected (65 years or older) & <=289 controls (65 years or older with PSA<4)



ASSOCIATION STUDIES

FIG. 18A

PG1 (8p23)

POPULATIONS	AFFECTED N= [275;491]			UNAFFECTED N=[130;313]
	ALL CASES	SPORADIC CASES	FAMILIAL CASES	CONTROLS
characteristics of populations	<=491 all cases	<=294 sporadics cases	<=197 familial cases	<28 unaffected (65 years or older) & <=289 controls (65 years or older with PSA<4)



name of markers	PG1	Polym.	Freq(cas)	Freq(controls)	abs diff % (fq(cases)– (fq(controls))	Odd Ratio	Pvalue	Freq(randoms)	Attributable Risk
99-1485/251	prom	G*/T	0.32	0.24	7.4	1.44	2.53E–02	0.29	17.58
99-622/95	in1	G/T	0.52	0.42	10.1	1.51	9.64E–03	ND$	ND
99-619/141	in1	C/T	0.28	0.22	5.8	1.37	6.93E–02	ND	ND
4-76/222	in1	G/A	0.43	0.38	5	1.23	1.57E–01	0.41	13.15
4-77/151	in1	G/C	0.34	0.26	7.4	1.43	1.35E–02	0.31	18.16
4-71/233	in1	A/G	0.34	0.26	8.3	1.49	1.43E–02	0.28	18.64
4-72/127	in1	A/G	0.36	0.30	5.7	1.29	9.43E–02	0.31	13.25
4-73/134	in1	G/C	0.52	0.42	9.7	1.48	7.29E–03	0.52	26.76
99-610/250	in1	G/A	0.43	0.37	6.2	1.30	8.33E–02	ND	ND
99-609/225	in1	A/T	0.37	0.30	7	1.36	4.83E–02	ND	ND
4-90/283	in2	A/C	0.29	0.25	4.4	1.25	1.68E–01	0.28	9.32
99-602/258	in2	A/G	0.33	0.25	7.4	1.44	2.69E–02	ND	ND
99-600/492	in3	T/A	0.34	0.34	0.3	1.01	7.52E–01	ND	ND
99-598/130	in4	G/A	0.35	0.25	9.2	1.55	7.29E–03	ND	ND
99-217/277	in4	T/C	0.31	0.28	3.8	1.20	1.07E–01	0.28	8.46
99-576/421	in6	G/C	0.27	0.17	9.2	1.72	3.18E–03	0.24	18.40
4-61/269	3'UTR	G/A	0.01	0.00	0.3	1.76	0,527§	ND	ND
4-66/145	3'UTR	C/T	0.25	0.19	6.2	1.43	4.68E–03	0.24	13.16
4-67/40	3'UTR	T/C	0.25	0.20	4.9	1.33	2.39E–02	0.24	10.97

§ Test Fisher–$ ND: Not done –* disease associated allele / not associated allele

FIG. 18B

FIG. 19A

HAPLOTYPE FREQUENCY ANALYSIS

POPULATIONS	AFFECTED	UNAFFECTED
sample sizes	CASES (n=491)	CONTROLS (n=317)
characteristics of populations	294 sporadic cases + 197 familial cases	28 unaffected (65 years or older) + 289 controls (65 years or older with PSA<4)

PG1 (8p23)			4-14/240	99-217/277	4-66/145	99-221/377
				in4	3'UTR	
distance between mks			<100kb>	<17kb>	<43kb>	
size (cases vs controls)			481vs305	481vs302	481vs300	481vs303
frequency % (cases/controls)			65,7/62,1(C)	31,3/27,5(C)	25,1/19(C)	42,7/42,91 (A)
abs diff freq. all.(cases-controls)			3.6	3.8	6.2	0
pvalue			1.47E-01	1.07E-01	4.68E-03	7.52E-01
Hardy Weindeberg Disequilibrium	cases		5.84E-01	6.55E-01	2.54E-01	5.84E-01
	controls		4.80E-01	2.21E-01	3.71E-01	2.54E-01
HAP 1 <43kb>		451 vs 297			C	A
HAP 2 <17kb>		451 vs 296		T	C	
HAP 3 <117kb>		452 vs 299	C		C	
HAP 4 <100kb>		479 vs 302	C	T		
HAP 5 <60kb>		476 vs 300		T		A
HAP 6 <160kb>	PT2	476 vs 303	C			C
HAP 7 <160kb>		447 vs 297	C		C	A
HAP 8 <60kb>		446 vs 294		T	C	A
HAP 9 <117kb>		450 vs 296	C	T	C	
HAP 10 <160kb>	PT3	474 vs 300	C	T		A
HAP 11 <160kb>	PT4	445 vs 294	C	T	C	A

haplotype frequencies		Odd ratio	Chi-S	Pvalue	
cases	controls				
0.116	0.067	1.83	9.85	(1.7e-03)	***
0.243	0.183	1.43	7.49	(6.2e-03)	**
0.182	0.130	1.49	7.18	(7.3e-03)	**
0.217	0.188	1.20	1.88	(1.7e-01)	*
0.155	0.132	1.20	1.54	(2.1e-01)	*
0.373	0.346	1.12	1.16	(2.7e-01)	*
0.095	0.042	2.39	14.62	(1.3e-04)	****
0.117	0.065	1.93	11.33	(7.3e-04)	***
0.178	0.125	1.53	7.80	(5.2e-03)	**
0.114	0.089	1.32	2.44	(1.1e-01)	*
0.095	0.032	3.18	21.59	(3.4e-06)	*****

FIG. 19B

HAPLOTYPE FREQUENCY ANALYSIS

PG1 (8p23)

markers of haplotype Max	4-14/240	99-217/277 in4	4-66/145 3'UTR	99-221/377
	C	T	C	A
distance between mks	<100kb>	<17kb>	<43kb>	

PG1	sample sizes	haplotype frequencies		odd ratio	chi-S	P value	
	cases vs control	cases	controls				
cases vs control	455 vs 294	0.095	0.032	3.18	21.59	3.40E-06	******
cases (<=65 years) vs controls	171 vs 294	0.105	0.032	3.56	20.91	4.60E-06	******
cases (>65 years) vs control	271 vs 294	0.079	0.032	2.60	12.13	4.80E-04	****
sporadic cases vs controls	266 vs 294	0.096	0.032	3.23	19.73	8.60E-06	******
sporadic cases (<=65 years) vs controls	85 vs 294	0.095	0.032	3.20	12.04	5.00E-04	****
sporadic cases (>65 years) vs controls	178 vs 294	0.085	0.032	2.82	12.75	3.50E-04	****
informative sporadic cases vs controls	67 vs 294	0.062	0.032	2.00	2.70	9.40E-02	**
familial cases vs controls	179 vs 294	0.098	0.032	3.32	18.33	1.80E-05	*****
familial cases (<=65 years) vs controls	86 vs 294	0.112	0.032	3.83	17.98	2.20E-05	*****
familial cases (>65 years) vs controls	93 vs 294	0.075	0.032	2.48	6.59	1.00E-02	**
familial cases (>=3 caP) vs controls	79 vs 294	0.123	0.032	4.26	21.33	3.70E-06	******

FIG. 20

HAPLOTYPE FREQUENCY ANALYSIS (PG1)

Markers in PG1		
size (cases vs controls)		
allelic frequency % (cases / controls)		
allelic frequency % (randoms)		
diff freq. all. % (cases-controls)		
pvalue (cases vs controls)		
Odd Ratio		
Attributable Risk %		
Hardy Weindeberg Disequilibrium	cases	
	controls	
haplotype 1	2 MKS	339 vs 167
haplotype 2	3 MKS	330 vs 122
haplotype 3	4 MKS	312 vs 122
haplotype 4	5 MKS	311 vs 121
haplotype 5	6 MKS	309 vs 121
haplotype 6	7 MKS	290 vs 99

99-622/95	4-77/151	4-71/233	4-73/134	99-598/130	99-576/421	4-66/145
G/T	C/G	A/G	C/G	A/G	C/G	C/T
in1				in4	in6	3'UTR
336 vs 108	363 vs 173	336 vs 130	352 vs 129	347 vs 126	355 vs 129	456 vs 306
52/42 (G)	34/26 (G)	34/26 (A)	52/42 (G)	35/25 (G)	27/17 (G)	25/19 (C)
ND	31 (G)	28 (A)	52 (G)	ND	24 (G)	24 (C)
10.1	7.4	8.3	9.7	9.2	9.2	6.2
9.64E-03	1.35E-02	1.43E-02	7.29E-03	7.29E-03	3.18E-03	4.68E-03
**	**	**	**	**	***	***
1.51	1.43	1 49	1.48	1.55	1.72	1.43
ND	18 16	18 64	26 76	ND	8 46	13.16
7.52E-01	7.52E-01	5.84E-01	7.52E-01	7.52E-01	7.52E-01	3.43E-01
4 39E-01	4.03E-01	1.21E-01	7.52E-01	6.52E-02	7.52E-01	1.29E-01
	G					C
		A		G	G	C
		A	G	G	G	C
	G	A	G	G	G	C
G	G	A	G	G	G	C

haplotype frequencies		Odd Ratio	Attributable Risk %	Pvalue (cases vs controls)	
cases	controls				
0.263	0.152	1.99	18.55	(6.7e-05)	****
0.259	0.147	2 02	ND	(3.9e-04)	***
0.259	0.147	2 02	ND	(4.1e-04)	***
0.26	0.148	2.01	ND	(4.8e-04)	***
0.258	0 149	2	ND	(5.3e-04)	***
0 255	0 146	2	ND	(1 6e-03)	***

ND Not Done

FIG. 21

Comparison of Pvalue between nb of mks for haplotype (19 mks of PG1)

GENE	# of markers	# of 2 mks combinations	# of 3 mks combinations	# of mks combinations
PG1	19	171	969	3876